News and History
-

Gilead to Acquire Tubulis for $5 Billion to Further Strengthen Oncology Pipeline
Read More: Gilead to Acquire Tubulis for $5 Billion to Further Strengthen Oncology PipelineOn Apr. 7, 2026, Gilead Sciences announced it has entered into a definitive agreement to acquire Tubulis, a
-

Life Science Industry’s Rapid Growth in Washington State Challenged by NIH Budget Cuts
Read More: Life Science Industry’s Rapid Growth in Washington State Challenged by NIH Budget CutsOn Apr. 7, 2026, LifeScienceHistory.com, formerly WashingtonLifeScience.com, announces release of a report highlighting the challenges of Washington State’s
-

Zhang Kai, Yale scientist leaves for China university
Read More: Zhang Kai, Yale scientist leaves for China universityOn Apr. 2, 2026, Zhang Kai, a rising cryo-electron microscopy researcher, has resigned from his tenure-track position at
-

FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
Read More: FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictionsOn Apr. 1, 2026, Eli Lilly announced the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for
-

China Tops U.S. in R&D Spending
Read More: China Tops U.S. in R&D SpendingOn Mar. 31, 2026, the Organisation for Economic Co-operation and Development (OECD), reports that China has officially crept
-

Biogen to Acquire Apellis for $5.6 billion, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease
Read More: Biogen to Acquire Apellis for $5.6 billion, Enhancing the Company’s Growth Portfolio in Immunology and Rare DiseaseOn Mar. 31, 2026, Biogen and Apellis Pharmaceuticals announced the companies have entered into a definitive agreement under
-

Lilly to acquire Centessa Pharma to advance treatments for sleep-wake disorders in deal worth up to $7.8 Billion
Read More: Lilly to acquire Centessa Pharma to advance treatments for sleep-wake disorders in deal worth up to $7.8 BillionOn Mar. 31, 2026, Eli Lilly and Centessa Pharmaceuticals, a clinical-stage company developing a new class of medicines
-

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Read More: FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular AtrophyOn Mar. 30, 2026, Biogen announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of
-

China biotech deals hit record as innovative drugs draw interest of multinationals
Read More: China biotech deals hit record as innovative drugs draw interest of multinationalsOn Mar. 29, 2026, The South China Morning Post reported the cross-border outlicensing activities of Chinese biotech firms
-

Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly
Read More: Insilico Medicine secures $2.75 billion drug collaboration with Eli LillyOn Mar. 29, 2026, generative-AI drug developer Insilico Medicine announced that it has agreed to a global licensing
-

NIH restrictions on foreign research partnerships significantly impacted 1 in 4 U.S. scientists
Read More: NIH restrictions on foreign research partnerships significantly impacted 1 in 4 U.S. scientistsOn Mar. 27, 2026, a STAT survey conducted of nearly 1,000 National Institutes of Health (NIH) -supported scientists,
-

Novartis to acquire Excellergy for $2 Billion, building on allergy leadership with next-generation anti-IgE innovation
Read More: Novartis to acquire Excellergy for $2 Billion, building on allergy leadership with next-generation anti-IgE innovationOn Mar. 27, 2026, Novartis announced an agreement to acquire Excellergy, a private biotech company developing next-generation anti-IgE
-

Implantable ‘Living Pharmacy’ Produces Multiple Drugs Inside the Body
Read More: Implantable ‘Living Pharmacy’ Produces Multiple Drugs Inside the BodyOn Mar. 27, 2026, A multi-institutional team of scientists, co-led by Northwestern University, has taken a crucial step
-

US measles cases top 1,500 as Texas outbreak grows
Read More: US measles cases top 1,500 as Texas outbreak grows -

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Read More: Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)On Mar. 27, 2026, Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration(FDA) has granted accelerated approval
-

PTAB sides with Broad Institute over University of California on patent priority for use of CRISPR in eukaryotic cells
Read More: PTAB sides with Broad Institute over University of California on patent priority for use of CRISPR in eukaryotic cellsOn Mar. 26, 2026, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (USPTO and PTAB,
-

Largest Animal Health Emergency in U.S. History Continues as HPAI Devastates Indiana
Read More: Largest Animal Health Emergency in U.S. History Continues as HPAI Devastates IndianaOn Mar. 26, 2026, Indiana’s poultry industry continues to face significant challenges as outbreaks of highly pathogenic avian
-

Merck to Acquire Terns Pharmaceuticals for $5.7 Billion, Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia
Read More: Merck to Acquire Terns Pharmaceuticals for $5.7 Billion, Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid LeukemiaOn Mar. 25, 2026, Merck, and Terns Pharmaceuticals, a clinical-stage oncology company, announced that the companies have entered
-

‘Dead End’: Radical 20-Year Study Reveals Genetic Cloning Hits a Limit
Read More: ‘Dead End’: Radical 20-Year Study Reveals Genetic Cloning Hits a LimitOn Mar. 25, 2026, researchers, led by scientists at the University of Yamanashi in Japan, cloned a single
-

WHO Data Show Pertussis (Whooping Cough) Rising in Western Pacific and Europe
Read More: WHO Data Show Pertussis (Whooping Cough) Rising in Western Pacific and EuropeOn Mar. 25, 2026, according to the latest data published by the World Health Organization (WHO), globally, 941,582


